Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Plain-language summary

This study examines the heart-protective (cardioprotective) effects of the drug Ertugliflozin on the fat tissue surrounding the heart (epicardial fat). It enrolled patients with type 2 diabetes who were scheduled for cardiac bypass or vascular surgery. The study was conducted in Early Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Early Phase 1

Status

Completed

Sponsor

Stanford University

Intervention

Ertugliflozin

Start date

7/1/2020

Estimated completion

12/31/2023

Countries

United States

Related genes

Locations

• Stanford, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass surgery or vascular surgery
* history of Diabetes Mellitus Type 2 currently diet controlled, or on metformin or dpp4 inhibitors

Exclusion Criteria:

* allergy or intolerance to interventional medication
* currently taking insulin, glp-1 inhibitors, or sulfonylureas